Vestal Point Capital LP Has $34.88 Million Stock Holdings in Amicus Therapeutics, Inc. $FOLD

Key Points

• Vestal Point Capital LP increased its stake in Amicus Therapeutics by 27.6% in Q1, totaling 4,275,000 shares worth approximately $34.88 million.
• Amicus Therapeutics currently holds a market cap of $2.34 billion with a 12-month stock price range of $5.51 to $12.65.
• Research analysts have a consensus rating of "Moderate Buy"** for Amicus Therapeutics, with an average price target set at **$16.22**.

Vestal Point Capital LP lifted its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 27.6% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,275,000 shares of the biopharmaceutical company's stock after acquiring an additional 925,000 shares during the period. Amicus Therapeutics accounts for approximately 2.5% of Vestal Point Capital LP's holdings, making the stock its 13th biggest position. Vestal Point Capital LP owned approximately 1.39% of Amicus Therapeutics worth $34,884,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in FOLD. Nuveen LLC acquired a new stake in Amicus Therapeutics during the first quarter valued at approximately $28,741,000. Orbimed Advisors LLC lifted its stake in Amicus Therapeutics by 300.7% during the fourth quarter. Orbimed Advisors LLC now owns 2,285,400 shares of the biopharmaceutical company's stock valued at $21,528,000 after purchasing an additional 1,715,100 shares during the last quarter. Prosight Management LP acquired a new stake in Amicus Therapeutics during the fourth quarter valued at approximately $8,666,000. D. E. Shaw & Co. Inc. lifted its stake in Amicus Therapeutics by 132.7% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,560,410 shares of the biopharmaceutical company's stock valued at $14,699,000 after purchasing an additional 889,968 shares during the last quarter. Finally, Osterweis Capital Management Inc. acquired a new stake in Amicus Therapeutics during the first quarter valued at approximately $6,730,000.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Morgan Stanley raised shares of Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a research note on Thursday, July 17th. Wall Street Zen downgraded shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday, August 30th. Seven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $16.00.

Amicus Therapeutics Trading Down 0.4%

Shares of NASDAQ:FOLD traded down $0.03 during mid-day trading on Friday, hitting $7.99. The stock had a trading volume of 5,558,774 shares, compared to its average volume of 3,714,259. The company has a market cap of $2.46 billion, a PE ratio of -66.58 and a beta of 0.55. The company has a debt-to-equity ratio of 1.92, a quick ratio of 2.29 and a current ratio of 3.21. The company's 50 day moving average is $6.74 and its 200-day moving average is $7.06. Amicus Therapeutics, Inc. has a 12-month low of $5.51 and a 12-month high of $12.65.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.